Esophagogastroduodenoscopy Screening Intentions During the COVID-19 Pandemic in Japan: Web-Based Survey.
Akahane T, Nakanishi Y, Yoshiji H, Akahane M.JMIR Cancer. 2022 Nov 11;8(4):e40600.

Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis.
Murata K, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H. Int J Mol Med. 2022 Aug;50(2):101.

Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Narita H, Kawaratani H, Shibamoto A, Takeda S, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Nishimura N, Hokuto D, Sho M, Yoshiji H. Clin J Gastroenterol. 2022 Jun 30.

The Usefulness of the Athens Insomnia Scale for Evaluating Sleep Disturbance in Patients with Chronic Liver Disease Comparing with Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale.
Kawaratani H, Miyaaki H, Hiraoka A, Nakao K, Hiasa Y, Yoshiji H, Okita K, Koike K. Medicina (Kaunas). 2022 May 30;58(6):741.

Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H. Dig Liver Dis. 2022 May 2:S1590-8658(22)00257-2.

Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.
Namisaki T, Tsuji Y, Kitade M, Yorioka N, Fujinaga Y, Sawada Y, Nishimura N, Kitagawa K, Inoue T, Takaya H, Kaji K, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. In Vivo. 2022 May-Jun;36(3):1477-1484.

Laser-cut-type versus braided-type covered self-expandable metallic stents for distal biliary obstruction caused by pancreatic carcinoma: a retrospective comparative cohort study.
Kitagawa K, Mitoro A, Ozutsumi T, Furukawa M, Fujinaga Y, Seki K, Nishimura N, Sawada Y, Kaji K, Kawaratani H, Takaya H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Clin Endosc. 2022 May;55(3):434-442.

Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H. Indian J Gastroenterol. 2022 Apr;41(2):169-180.

Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis.
Enomoto M, Takaya H, Namisaki T, Fujinaga Y, Nishimura N, Sawada Y, Kaji K, Kawaratani H, Moriya K, Akahane T, Inoue T, Matsumoto M, Yoshiji H. Hepatol Res. 2022 Apr;52(4):390-400.

ADAMTS13, VWF, and Endotoxin Are Interrelated and Associated with the Severity of Liver Cirrhosis via Hypercoagulability.
Takaya H, Namisaki T, Asada S, Iwai S, Kubo T, Suzuki J, Enomoto M, Tsuji Y, Fujinaga Y, Nishimura N, Sawada Y, Kaji K, Kawaratani H, Moriya K, Akahane T, Matsumoto M, Yoshiji H. J Clin Med. 2022 Mar 26;11(7):1835.

Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
Kawaratani H, Kondo Y, Tatsumi R, Kawabe N, Tanabe N, Sakamaki A, Okumoto K, Uchida Y, Endo K, Kawaguchi T, Oikawa T, Ishizu Y, Hige S, Takami T, Terai S, Ueno Y, Mochida S, Takikawa Y, Torimura T, Matsuura T, Ishigami M, Koike K, Yoshiji H. J Clin Med. 2022 Mar 12;11(6):1571.

Protein-losing gastroenteropathy complicated with asymptomatic primary biliary cholangitis, refractory to immunosuppressant, and improved by Helicobacter pylori eradication: a case report.
Tanaka M, Kawaratani H, Noguchi R, Koizumi A, Shibamoto A, Kaji K, Shimozato N, Kojima K, Nishimura Y, Yoshiji H. BMC Gastroenterol. 2022 Mar 7;22(1):101.

Clinical Significance of Serum Zinc Levels on the Development of Sarcopenia in Cirrhotic Patients. Murata K, Namisaki T, Fujimoto Y, Takeda S, Enomoto M, Takaya H, Tsuji Y, Shibamoto A, Suzuki J, Kubo T, Iwai S, Tomooka F, Tanaka M, Kaneko M, Asada S, Koizumi A, Yorioka N, Matsuda T, Ozutsumi T, Ishida K, Ogawa H, Takagi H, Fujinaga Y, Furukawa M, Sawada Y, Nishimura N, Kitagawa K, Sato S, Kaji K, Inoue T, Asada K, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Cancer Diagn Progn. 2022 Mar 3;2(2):184-193.

Liver Biopsy-confirmed Primary Hepatic Amyloidosis with Only Jaundice as the Initial Symptom: An Autopsy Case Report.
Ueno H, Douhara A, Osaki Y, Koizumi A, Yorioka N, Ueda S, Tsutsumi M, Yoshiji H. Intern Med. 2022 Feb 26.

Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems.
Takaya H, Namisaki T, Matsumoto K, Suzuki J, Murata K, Tsuji Y, Nakanishi K, Kaji K, Kitade M, Noguchi R, Yoshiji H. J Clin Med. 2022 Jan 15;11(2):434.

Current drug therapy for hepatocellular carcinoma.
Yoshiji H. Nihon Shokakibyo Gakkai Zasshi. 2022;119(5):389-402.

Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
Shimozato N, Namisaki T, Okano A, Ohana M, Kinoshita D, Kawasaki T, Aihara Y, Nakatani T, Kinoshita H, Ann T, Saito KO, Yoshida M, Yoshiji H. Anticancer Res. 2022 Jan;42(1):173-183.

New Horizon on Gut Microbiome and Cancers: Recent Information on Pathogenesis and Treatment. Fukui H.
American Journal of Internal Medicine. 2022 May;10(3):62-70.

Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity.
Fujimoto Y, Kaji K, Nishimura N, Enomoto M, Murata K, Takeda S, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. World J Gastroenterol. 2021 Dec 28;27(48):8323-8342.

Angiotensin Receptor Blockers Potentiate the Protective Effect of Branched-Chain Amino Acids on Skeletal Muscle Atrophy in Cirrhotic Rats.
Takeda S, Kaji K, Nishimura N, Enomoto M, Fujimoto Y, Murata K, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Yoshiji H. Mol Nutr Food Res. 2021 Dec;65(24):e2100526.

Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures.
Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Hepatol Res. 2021 Dec;51(12):1181-1195.

A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites.
Kawaratani H, Sawai H, Onishi M, Kogiso T, Shimada N, Uojima H, Nakajima T, Matsumoto N, Ikejima K, Ishikawa T, Terai S, Motoyama H, Komori A, Hirashima N, Saito S, Eguchi Y, Nojima M, Kawai Y, Tateyama M, Yoshiji H, Tanaka Y. Liver Int. 2021 Dec;41(12):2944-2953.

Association between Equol Production Status and Nonalcoholic Steatohepatitis.
Akahane T, Kaya D, Noguchi R, Kaji K, Miyakawa H, Fujinaga Y, Tsuji Y, Takaya H, Sawada Y, Furukawa M, Kitagawa K, Ozutsumi T, Kawaratani H, Moriya K, Namisaki T, Yoshiji H. Int J Mol Sci. 2021 Nov 2;22(21):11904.

The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria.
Takaya H, Namisaki T, Takeda S, Kaji K, Ogawa H, Ishida K, Tsuji Y, Takagi H, Ozutsumi T, Fujinaga Y, Furukawa M, Kitagawa K, Nishimura N, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. J Clin Med. 2021 Oct 21;10(21):4838.

Comparison of the efficacy and safety between palliative biliary stent placement and duct clearance among elderly patients with choledocholithiasis: a propensity score-matched analysis.
Kitagawa K, Mitoro A, Ozutsumi T, Furukawa M, Fujinaga Y, Nishimura N, Sawada Y, Namisaki T, Akahane T, Yoshiji H. BMC Gastroenterol. 2021 Oct 10;21(1):369.

Enhanced liver fibrosis score as a surrogate of liver-related complications and mortality in primary biliary cholangitis.
Fujinaga Y, Namisaki T, Takaya H, Tsuji Y, Suzuki J, Shibamoto A, Kubo T, Iwai S, Tomooka F, Takeda S, Fujimoto Y, Enomoto M, Murata K,